🏛️ Verified NIH Record • Updated 2026-05-18

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) (NCT06898957)

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Amgen

🩺 Plain-English Summary (8th-Grade Level)

The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (6 items).

Location: City of Hope Orange County Lennar Foundation Cancer Center — Irvine, California

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Prior delta-like ligand 3 (DLL3) or B7 homolog 3 (B7-H3) targeted therapy.
  • Prior exposure to topoisomerase I inhibitors or antibody-drug conjugate (ADC) with topoisomerase I inhibitor payload.
  • Symptomatic central nervous system (CNS) metastases. Note: Participants with asymptomatic brain metastases are eligible as defined in the protocol.
  • History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required corticosteroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
  • Baseline requirement of supplemental oxygen.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (36 Sites)

  • City of Hope Orange County Lennar Foundation Cancer Center — Irvine, California
  • Yale New Haven Hospital — New Haven, Connecticut
  • Moffitt Cancer Center — Tampa, Florida
  • Dana Farber Cancer Institute — Boston, Massachusetts
  • Siteman Cancer Center — St Louis, Missouri
  • Sanford Roger Maris Cancer Center — Fargo, North Dakota
  • Cleveland Clinic Foundation — Cleveland, Ohio
  • Sanford Oncology Clinic and Pharmacy — Sioux Falls, South Dakota
  • University of Texas MD Anderson Cancer Center — Houston, Texas
  • Swedish Medical Center — Seattle, Washington
  • Fred Hutchinson Cancer Center — Seattle, Washington
  • CHU de Quebec Hopital de l Enfant Jesus — Québec, Quebec
  • Shandong Cancer Hospital — Jinan, Shandong
  • West China Hospital of Sichuan University — Chengdu, Sichuan
  • Fujian Cancer Hospital — Fuzhou,
  • Institut Bergonie — Bordeaux,
  • Centre Leon Berard — Lyon,
  • Institut Universitaire du Cancer Toulouse Oncopole — Toulouse,
  • Gustave Roussy — Villejuif,
  • Universitaetsklinikum Essen — Essen,
  • Henry Dunant Hospital Center — Athens,
  • Alexandra Hospital — Athens,
  • European Interbalkan Medical Center — Thessaloniki,
  • Iatriko Diavalkaniko Thessalonikis — Thessaloniki,
  • Semmelweis Egyetem — Budapest,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗